Strides Pharma Science's Q3FY20 consolidated revenues came in at Rs735.3cr, demonstrating 28% yoy and 2% qoq growth.
Consolidated EBITDA stood at Rs185.1cr, up 185% yoy and 23% qoq. Reported EBITDA margins came in at 25.2%, a new milestone for Strides.
The regulated markets continued their positive trajectory. US markets clocked $66mn quarterly run-rate with ~90% front-end driven revenues.
Arun Kumar, Founder, remarked, “We are pleased to announce a strong financial performance in the Q3FY20. Our contrarian strategies continue to play out for the regulated markets, which are now delivering growth with industry-leading post R&D EBITDA margins."
Stock View:
Strides Pharma Science Ltd is currently trading at Rs483 up by Rs36.1 or 8.08% from its previous closing of Rs446.90 on the BSE.
The scrip opened at Rs442.20 and has touched a high and low of Rs483.60 and Rs442.20 respectively. So far 25,36,738 (NSE+BSE) shares were traded on the counter.
The current market cap of the company is Rs4,002.12cr.
For Quick Trial – 8871888787
or mail us here - support@researchicon.com
or visit - http://www.researchicon.com/free-trial
Post a Comment